- Home
- EAT vs VRNA Comparison
EAT vs VRNA Comparison
Compare EAT & VRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EAT
- VRNA
- Stock Information
- Founded
- EAT 1975
- VRNA 2005
- Country
- EAT United States
- VRNA United Kingdom
- Employees
- EAT N/A
- VRNA N/A
- Industry
- EAT Restaurants
- VRNA Biotechnology: Pharmaceutical Preparations
- Sector
- EAT Consumer Discretionary
- VRNA Health Care
- Exchange
- EAT Nasdaq
- VRNA Nasdaq
- Market Cap
- EAT 7.0B
- VRNA 8.3B
- IPO Year
- EAT N/A
- VRNA 2017
- Fundamental
- Price
- EAT $123.05
- VRNA $106.91
- Analyst Decision
- EAT Buy
- VRNA Buy
- Analyst Count
- EAT 15
- VRNA 11
- Target Price
- EAT $175.07
- VRNA $114.10
- AVG Volume (30 Days)
- EAT 1.4M
- VRNA 1.5M
- Earning Date
- EAT 10-29-2025
- VRNA 11-03-2025
- Dividend Yield
- EAT N/A
- VRNA N/A
- EPS Growth
- EAT 144.71
- VRNA N/A
- EPS
- EAT 8.32
- VRNA N/A
- Revenue
- EAT $5,384,200,000.00
- VRNA $221,673,000.00
- Revenue This Year
- EAT $6.91
- VRNA $909.96
- Revenue Next Year
- EAT $5.16
- VRNA $76.47
- P/E Ratio
- EAT $14.65
- VRNA N/A
- Revenue Growth
- EAT 21.95
- VRNA N/A
- 52 Week Low
- EAT $82.24
- VRNA $31.09
- 52 Week High
- EAT $192.22
- VRNA $106.94
- Technical
- Relative Strength Index (RSI)
- EAT 29.44
- VRNA 72.60
- Support Level
- EAT $125.55
- VRNA $105.78
- Resistance Level
- EAT $130.50
- VRNA $106.86
- Average True Range (ATR)
- EAT 4.31
- VRNA 0.16
- MACD
- EAT -0.30
- VRNA -0.04
- Stochastic Oscillator
- EAT 14.81
- VRNA 98.26
About EAT Brinker International Inc.
Brinker International Inc operates casual dining restaurants under the brand's Chili Grill and Bar (Chili's) and Maggiano's Little Italy (Maggiano's). Chili's falls in the Bar and Grill category of casual dining. Its menu features Fresh Mex and Fresh Tex favorites including signature items such as slow-smoked baby back ribs, craft burgers, fajitas, and bottomless chips and salsa paired with tableside guacamole. Maggiano's is an Italian restaurant brand with a full lunch and dinner menu offering chef-prepared, such as appetizers, chicken, seafood, veal and prime steaks, and desserts. The company generates maximum revenue from Chili's segment.
About VRNA Verona Pharma plc
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.